Markers of PI3K/Akt, ER & AR pathways and Ki67 expression in relation to tamoxifen outcome in ER plus breast cancer

被引：0
|
作者：
Campbell, C.
Mathew, J.
Ellis, I.
Finlay, P.
Green, A.
Bradbury, I.
Borgquist, S.
Elebro, K.
Politz, O.
Haegebarth, A.
Gee, J. M.
Robertson, J. F.
机构：
[1] Frontier Sci Scotland, Inverness, Scotland
[2] Peterborough City Hosp, Peterborough, Cambs, England
[3] Nottingham Univ Hosp, Nottingham, England
[4] Cardiff Univ, Cardiff, S Glam, Wales
[5] Aarhus Univ, Aarhus, Denmark
[6] Skane Univ Hosp, Malmo, Sweden
[7] Bayer, Berlin, Germany
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P2-03-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-03-02
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Prediction of response to neoadjuvant chemotherapy in estrogen receptor positive (ER plus ) breast cancer by IHC4 or Ki67 alone
    Sheri, A.
    Smith, I. E.
    A'Hern, R.
    Jones, R.
    Parton, M.
    Johnston, S. R. D.
    Dowsett, M.
    CANCER RESEARCH, 2013, 73
  • [32] A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer
    Sirwan M. Hadad
    Lee B. Jordan
    Pankaj G. Roy
    Colin A. Purdie
    Takayuki Iwamoto
    Lajos Pusztai
    Stacy L. Moulder-Thompson
    Alastair M. Thompson
    BMC Cancer, 16
  • [33] Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2-primary breast cancer patients with preferential tamoxifen benefit
    Kruger, Dinja T.
    Beelen, Karin
    Opdam, Mark
    Sanders, Joyce
    van der Noort, Vincent
    Boven, Epie
    Linn, Sabine C.
    CANCER RESEARCH, 2018, 78 (04)
  • [34] PI3K SIGNALING REGULATES ER ACTIVITY VIA KMT2D IN ER+ BREAST CANCER
    Toska, E.
    Osmanbeyoglu, H. U.
    Castel, P.
    Chan, C.
    Hendrickson, R. C.
    Elkabets, M.
    CANCER DISCOVERY, 2017, 7 (05) : 455 - 455
  • [35] New link between PI3K pathway and ER levels in breast cancer revealed
    Strawson, Annabel
    EXPERT REVIEW OF PROTEOMICS, 2010, 7 (04) : 468 - 468
  • [36] PI3Kα/δ inhibitor, copanlisib is highly effective in ER-positive breast cancer
    De, Pradip
    Aske, Jennifer C.
    Williams, Casey
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Crosstalk between ER and PI3K signaling pathways in human luminal type breast cancer and its therapeutic implications
    Fu, Xiaoyong
    Nanda, Sarmistha
    Gillihan, Ryan M.
    Shea, Martin
    Creighton, Chad J.
    Hilsenbeck, Susan G.
    Lee, Adrian V.
    Schiff, Rachel
    Osborne, Kent C.
    CANCER RESEARCH, 2011, 71
  • [38] Dual inhibition of the PI3k/Akt and MEK5/ERK5 pathways in tamoxifen resistant breast cancer
    Wright, Thomas D.
    Hasan, Mahmud
    Witt-Enderby, Paula
    Cavanaugh, Jane
    CANCER RESEARCH, 2017, 77
  • [39] Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
    Ortega, Miguel A.
    Fraile-Martinez, Oscar
    Asunsolo, Angel
    Bujan, Julia
    Garcia-Honduvilla, Natalio
    Coca, Santiago
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [40] Calycosin induces apoptosis in osteosarcoma cell line via ERβ-mediated PI3K/Akt signaling pathways
    Tian, Wei
    Wang, Zhi-Wei
    Yuan, Bao-Ming
    Bao, Yong-Ge
    MOLECULAR MEDICINE REPORTS, 2020, 21 (06) : 2349 - 2356
12345